See more : home24 SE (H24.DE) Income Statement Analysis – Financial Results
Complete financial analysis of SenzaGen AB (SENZA.ST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SenzaGen AB, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Osteopore Limited (OSX.AX) Income Statement Analysis – Financial Results
- CureVac N.V. (CVAC) Income Statement Analysis – Financial Results
- Hangzhou Xili Intelligent Technology Co.,Ltd (688616.SS) Income Statement Analysis – Financial Results
- World Kinect Corporation (WKC) Income Statement Analysis – Financial Results
- Automotive Stampings and Assemblies Limited (ASAL.NS) Income Statement Analysis – Financial Results
SenzaGen AB (SENZA.ST)
About SenzaGen AB
SenzaGen AB develops, performs, and sells non-animal tests for assessing a substance's allergenicity. The company offers genomic allergen rapid detection (GARD)skin, an in vitro test to identify potential chemical skin sensitizers; GARDpotency, an in vitro add-on test to GARDskin for potency classification; GARDskin Dose-response, an in vitro test for quantitative skin sensitizing potency assessment of chemicals; and GARDair, an in vitro test for identifying chemical respiratory sensitizers, as well as GARDskin medical device, an in vitro skin sensitization testing for medical devices and solid materials. It also provides irritation and corrosion testing services. The company offers services through license partners and distributors. It has a collaboration agreement with the Research Institute for Fragrance Materials to develop tests for photosensitization. The company was incorporated in 2010 and is headquartered in Lund, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 49.87M | 41.77M | 15.42M | 7.96M | 2.72M | 2.00M | 1.15M | 498.00K | 1.75M | 1.62M |
| Cost of Revenue | 14.94M | 14.43M | 5.97M | 5.01M | -776.00K | -7.26M | -9.16M | 1.67M | 2.36M | 1.35M |
| Gross Profit | 34.93M | 27.34M | 9.45M | 2.95M | 3.50M | 9.26M | 10.31M | -1.18M | -607.00K | 273.00K |
| Gross Profit Ratio | 70.05% | 65.44% | 61.30% | 37.09% | 128.49% | 463.45% | 894.10% | -235.94% | -34.73% | 16.81% |
| Research & Development | 3.75M | 8.99M | 3.87M | 2.63M | 10.84M | 5.79M | 5.87M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 19.14M | 17.42M | 15.55M | 8.36M | 18.54M | 17.79M | 18.85M | 5.66M | 4.40M | 0.00 |
| Selling & Marketing | 26.79M | 21.61M | 21.23M | 20.84M | 16.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 45.93M | 39.03M | 36.78M | 29.20M | 18.54M | 17.79M | 18.85M | 5.66M | 4.40M | 1.58M |
| Other Expenses | 0.00 | -486.00K | 328.00K | 852.00K | 22.89M | 12.20M | 8.07M | 4.51M | 137.00K | 0.00 |
| Operating Expenses | 49.67M | 47.53M | 40.99M | 30.05M | 41.43M | 29.99M | 26.92M | 10.16M | 4.28M | 63.00K |
| Cost & Expenses | 64.61M | 61.96M | 46.96M | 35.06M | 40.65M | 22.73M | 17.76M | 11.83M | 6.63M | 1.41M |
| Interest Income | 564.00K | 171.00K | 187.00K | 76.00K | 184.00K | 125.00K | 12.00K | 1.00K | 0.00 | 0.00 |
| Interest Expense | 37.00K | 46.00K | 19.00K | 147.00K | 1.00K | 1.00K | 30.00K | 54.00K | 94.00K | 0.00 |
| Depreciation & Amortization | 8.19M | 9.42M | 4.27M | 1.78M | 2.99M | 1.33M | 600.00K | 277.00K | -1.98M | 25.00K |
| EBITDA | -13.54M | -15.35M | -27.08M | -25.39M | -34.75M | -19.28M | -15.99M | -11.06M | -4.60M | 361.36K |
| EBITDA Ratio | -27.14% | -25.32% | -175.58% | -291.47% | -1,275.26% | -965.45% | -1,387.16% | -2,220.48% | -262.93% | 28.26% |
| Operating Income | -14.74M | -20.19M | -31.53M | -27.10M | -37.93M | -20.73M | -16.61M | -11.34M | -4.88M | 434.00K |
| Operating Income Ratio | -29.56% | -48.34% | -204.47% | -340.51% | -1,392.33% | -1,038.11% | -1,440.24% | -2,276.31% | -279.35% | 26.72% |
| Total Other Income/Expenses | -7.24M | -4.77M | -125.00K | -70.00K | 184.00K | 124.00K | -18.00K | -53.00K | 43.00K | -98.00K |
| Income Before Tax | -21.98M | -24.96M | -31.37M | -27.17M | -37.74M | -20.61M | -16.62M | -11.39M | -4.84M | 336.00K |
| Income Before Tax Ratio | -44.07% | -59.76% | -203.38% | -341.39% | -1,385.57% | -1,031.90% | -1,441.80% | -2,286.95% | -276.89% | 20.69% |
| Income Tax Expense | 121.00K | -50.00K | -19.00K | 147.00K | 12.49M | -4.52M | -3.55M | -2.48M | -1.98M | 74.00K |
| Net Income | -22.10M | -24.91M | -31.35M | -27.32M | -50.24M | -16.09M | -12.99M | -8.94M | -2.86M | 262.00K |
| Net Income Ratio | -44.31% | -59.64% | -203.26% | -343.24% | -1,844.24% | -805.71% | -1,126.97% | -1,795.58% | -163.44% | 16.13% |
| EPS | -0.91 | -1.03 | -1.30 | -1.28 | -3.11 | -1.04 | -1.61 | -0.83 | -0.26 | 0.05 |
| EPS Diluted | -0.91 | -1.03 | -1.30 | -1.28 | -3.11 | -1.04 | -1.61 | -0.81 | -0.26 | 0.05 |
| Weighted Avg Shares Out | 24.19M | 24.09M | 24.07M | 21.36M | 16.18M | 15.47M | 8.08M | 10.82M | 11.09M | 5.04M |
| Weighted Avg Shares Out (Dil) | 24.19M | 24.09M | 24.07M | 21.36M | 16.18M | 15.53M | 8.08M | 11.09M | 11.09M | 5.04M |
Source: https://incomestatements.info
Category: Stock Reports